美国芝加哥西北大学Feinberg医学院神经科Stern医师报告 ,烷化剂替莫唑胺 (temozolomide)治疗恶性神经胶质瘤具有长期的安全性和疗效 ,它使胶质瘤的长期治疗成为现实。该项研究纳入了 1 6例 2 6～ 5 2岁的神经胶质瘤病人 ,其中 1 4例病人的恶性度为 3级或 4级 ,2例为低度恶性。 Stern, MD, from the Feinberg School of Medicine at Northwestern University in Chicago, USA, reports that the long-term safety and efficacy of the alkylating agent temozolomide in the treatment of malignant gliomas has made long-term treatment of gliomas a reality. The study included 16 patients with gliomas ranging in age from 26 to 52 years, of whom 14 had grade 3 or 4 malignant disease and 2 had low grade malignancy.